Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients-Reference-Cited by-同舟云学术

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients

Published:2017-05-30 Issue:8 Volume:92 Page:E166-E168
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Ysebaert Loic¹^ORCID,Aurran-Schleinitz Thérèse²,Dartigeas Caroline³,Dilhuydy Marie-Sarah⁴,Feugier Pierre⁵,Michallet Anne-Sophie⁶^ORCID,Tournilhac Olivier⁷,Dupuis Jehan⁸,Sinet Pierre⁹,Albrecht Claire⁹,Cymbalista Florence¹⁰

Affiliation:

1. IUC Toulouse-Oncopole; Toulouse France

2. Institut Paoli-Calmettes, Boulevard de Sainte-Marguerite; Marseille France

3. Hôpital Bretonneau; Tours France

4. CHU de Bordeaux; Bordeaux France

5. CHU de Nancy; Nancy France

6. CHU Lyon Sud; Lyon France

7. CHU Estaing; Clermont-Ferrand France

8. Hôpital Henri Mondor; Créteil France

9. Janssen-Cilag, Issy-les-Moulineaux; France

10. Hôpital Avicenne; Bobigny France

Funder

Janssen France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24773/fullpdf

Reference6 articles.

1. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med.,2013

2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med.,2014

3. Jones J Hillmen P Coutre S 56th ASH Annual Meeting and Exposition 2014

4. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program;Dupuis;Clin Lymphoma Myeloma Leuk.,2015

5. Brown JR O'brien S Moslehi J oster 30 presented at the 2016 ASH Meeting on Hematologic Malignancies 2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study;Cancers;2024-03-20

2. The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When;Cancers;2023-09-02

3. Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada;Leukemia & Lymphoma;2023-04-22

4. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group;Leukemia & Lymphoma;2022-06-23

5. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?;Blood Advances;2021-12-17